BMS-265246
货号：
19168-1mg 基本售价：
686.0 元 规格：
1 mg
产品信息
概述| 货号 | 19168-1mg |
| 描述 | Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy.1 BMS-265246 is a cell-permeable inhibitor of Cdk1/cyclin B and Cdk2/cyclin E (IC50s = 6 and 9 nM, respectively).2 It less potently inhibits Cdk4/cyclin D (IC50 = 0.23 μM).2 BMS-265246 blocks the cycling of HCT116 cells (EC50 = 0.29-0.49 µM), resulting in cell cycle arrest in G2phase.3 |
性能| 供应商 | Cayman |
| 应用文献 |
1.Bettayeb, K.,Baunbaek, D.,Delehouze, C., et al. CDK inhibitors roscovitine and CR8 trigger Mcl-I down-regulation and apoptotic cell death in neuroblastoma cells. Genes Cancer 1(4), 369-380 (2010).
2.Misra, R.N.,Xiao, H.,Rawlins, D.B., et al. 1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: Highly potent 2,6-Difluorophenacyl analogues. Bioorganic & Medicinal Chemistry Letters 13(14), 2405-2408 (2003).
3.Sutherland, J.J.,Low, J.,Blosser, W., et al. A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators. Molecular Cancer Therapeutics 10(2), 242-254 (2011).
|
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥95% |
| 计算分子量 | 345.3 |
| 分子式 | C18H17F2N3O2 |
| CAS号 | 582315-72-8 |
| 稳定性 | ≥ 2 years |
声明| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |
